EVALUATION OF LABORATORY-IMMUNOLOGIC METHODS OF CARDIOVASCULAR PATHOLOGY IN PSORIATIC ARTHRITIS PATIENTS

Authors

  • Abdullaev U.S. Tashkent Medical Academy, Tashkent, Republic of Uzbekistan
  • Abdullaev Ulugbek Sayfullaevich Assistant of the Department of Internal Diseases Propaedeutics, Tashkent Medical Academy, Tashkent, Republic of Uzbekistan

Keywords:

psoriatic arthritis, cardiovascular diseases, laboratory-immunologic methods of research

Abstract

According to modern researchers, one of the most common comorbid diseases in patients with psoriatic arthritis (PsA) is cardiovascular disease (CVD). The presence of CVD in PsA increases the risk of cardiovascular complications (CVC) that lead to early disability in patients with this disease. In general, it was found that early diagnosis of CVD in PsA, not only can prevent CVC, but also can significantly improve the tactics of patient management, prevention of complications and improve the quality of life of patients with PsA

References

Eder L, Abji F, Rosen CF, et al. The association between obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol 2017; 44: 437–443.

Fagerli K.M., Kearsley-Fleet L., Mercer L.K., et al.Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumor-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register Rheumatol. (Oxford, England), 58 (2019), pp. 80-85.

Green A, Shaddick G, Charlton R, et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol 2020; 182: 714–720.

Hansson G.K. Inflammation and atherosclerosis: the end of a controversy Circulation, 136 (2017), pp. 1875-1877.

Holland R., Tillett W., Korendowych E., et al.Validation of the psoriatic arthritis impact of disease (PsAID) questionnaire and its potential as a single-item outcome measure in clinical practice Ann. Rheum. Dis., 77 (2018), pp. 343-347.

Husted J.A, Thavaneswaran A., Chandran V., Gladman D.D. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J. Rheumatol., 40 (2013), pp. 1349-1356.

Lockshin B., Balagula Y., Merola J.F. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis J. Am. Acad. Dermatol., 79 (2018), pp. 345-352.

Mahil S.K., McSweeney S.M., Kloczko E., et al. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol 2019; 181: 946–953.

Miller I.M., Skaaby T., Ellervik C., Jemec G.B. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis Br. J. Dermatol., 169 (2013), pp. 1180-1187.

Neiman A.L., Shin D.B., Wang x D.B. at al. /Prevalence of cardiovascular risk factors in patients with psoriasis // J. Am. Acad. Dermatology. 2006 - P. 55 -829-834.

Downloads

Published

2023-08-22

How to Cite

Abdullaev U.S., & Abdullaev Ulugbek Sayfullaevich. (2023). EVALUATION OF LABORATORY-IMMUNOLOGIC METHODS OF CARDIOVASCULAR PATHOLOGY IN PSORIATIC ARTHRITIS PATIENTS. World Bulletin of Public Health, 25, 24-28. Retrieved from https://scholarexpress.net/index.php/wbph/article/view/3103

Issue

Vol. 25 (2023): WBPH

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.